Down syndrome and acute lymphoblastic leukaemia

Area of Science:

• Pediatric Oncology
• Genetics
• Hematology

Background:

• Acute lymphoblastic leukemia in children with Down syndrome (ALL-DS) presents distinct clinical and biological characteristics.
• These include a lack of ALL in infants under 1 year, fewer chromosomal translocations, increased methotrexate sensitivity, and higher infection rates.
• Historically, ALL-DS outcomes were poorer than in non-DS counterparts (ALL-NDS).

Purpose of the Study:

• To evaluate current treatment outcomes for pediatric ALL-DS.
• To identify strategies for improving survival while minimizing treatment-related toxicities.
• To explore novel therapeutic approaches for ALL-DS.

Main Methods:

• Analysis of recent clinical data comparing ALL-DS and ALL-NDS patient outcomes.
• Risk-adapted therapy protocols were considered.
• Adjustment for biological differences between the two populations.

Main Results:

• Recent data show comparable outcomes between ALL-DS and ALL-NDS patients when using risk-adapted therapies.
• This comparability is observed after accounting for inherent biological differences.
• Children with ALL-DS face a higher risk of treatment-related toxicities.

Conclusions:

• Current risk-adapted therapies have made outcomes for pediatric ALL-DS comparable to ALL-NDS.
• Further intensification of chemotherapy may not improve survival due to increased toxicity risks.
• Future research should prioritize targeted, non-cytotoxic agents to maintain efficacy and reduce complications in ALL-DS.